COMPLETE KIT INCLUDEDbacteriostatic water, syringes, protocol and guide with every order

Certified by ISSCA in Peru and Colombia•ISSCA World Peptide ConferencePERU 2026•Certified by ISSCA in Peru and Colombia•ISSCA World Peptide ConferencePERU 2026•Certified by ISSCA in Peru and Colombia•ISSCA World Peptide ConferencePERU 2026•Certified by ISSCA in Peru and Colombia•ISSCA World Peptide ConferencePERU 2026•
BioPeptideX logoBioPeptideX
Back
Back to Insights

Insights

Retatrutide vs Tirzepatide: Which Is Better for Metabolic Research?

Mechanisms of action, clinical evidence, and technical differences between the two most-studied metabolic compounds of the moment.

Introduction

Two compounds currently dominate the conversation in metabolic research: Tirzepatide and Retatrutide. Both have produced unprecedented results in published clinical studies. But what is the real difference between them?

What is Tirzepatide?

Tirzepatide is a dual agonist of the GLP-1 and GIP receptors. It activates the GLP-1 receptor (reducing appetite, slowing gastric emptying, stimulating insulin) and the GIP receptor (enhancing insulin, modulating adipose tissue). The SURMOUNT-1 studies published in NEJM in 2022 reported average weight reductions of up to 22.5% over 72 weeks.

What is Retatrutide?

Retatrutide is a triple agonist of the GLP-1, GIP, and glucagon (GCG) receptors. Adding the glucagon receptor actively stimulates thermogenesis and increases energy expenditure — creating a metabolic effect on two fronts: reduced intake AND increased expenditure. Phase II studies published in NEJM in 2023 reported average weight reductions of up to 24.2% over 48 weeks — the highest results reported to date for a compound in this class.

Technical comparison

  • Tirzepatide: GLP-1 and GIP receptors, second generation, reduction up to 22.5%, FDA approved.
  • Retatrutide: GLP-1, GIP, and GCG receptors, third generation, reduction up to 24.2%, Phase III underway.

Which one to choose for research?

Research with Tirzepatide when: the study focuses on the GLP-1/GIP axis, it's being compared with Semaglutide, or more published clinical evidence is required.

Research with Retatrutide when: the greatest available metabolic-regulation potential is needed, thermogenesis mechanisms are being investigated, or effects on visceral adipose tissue are being studied.

Price and availability in Peru

  • Tirzepatide 10mg: S/. 280.80
  • Retatrutide 10mg: S/. 439.20

Both with 99% purity, verified COA, and cold-chain shipping across Peru and LATAM.

Conclusion

Tirzepatide and Retatrutide represent the cutting edge of research into incretin receptor agonists. The key difference is the third, glucagon receptor in Retatrutide, which turns an intake-reduction mechanism into bidirectional metabolic regulation. BioPeptideX is the reference supplier for both compounds in Peru and LATAM.

Important notice: products sold by BioPeptideX are intended exclusively for scientific research use. They are not therapeutic products and are not approved for human or veterinary use.
View Tirzepatide 10mgView Retatrutide 10mg← Back to Insights